N-Phenylpyridinium | 30718-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-Phenylpyridinium
• 英文别名: 1-Phenylpyridin-1-ium
• CAS: 30718-13-9
• 化学式: C₁₁H₁₀N
• 分子量: 156.207
• InChiKey: FHIWTZOWCILSIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  3.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  吡啶 、 苯酚 以 水 为溶剂， 生成 N-Phenylpyridinium
  参考文献：
  名称：

  水微滴中苯酚自发生成芳基碳正离子：空气-水界面上的芳香族 SN1 反应

  摘要：

  尽管苯酚在大量水中是稳定的，但我们报告了一种特殊现象，即苯酚在水微滴中自发转化为苯基碳正离子（Ph +）。空气-水界面处的高电场被认为会破坏酚类 Csp 2 –OH 键，形成 Ph +，通过质谱分析，Ph + 与苯酚保持平衡。尽管酚类 Csp 2 –OH 键的无催化剂活化具有挑战性，但我们在水性微滴中检测到高达 70% 的苯酚转化为 Ph + 。酚类化合物中各种给电子和吸电子取代基都能很好地耐受这种转变。水微滴中的Ph +可以与各种亲核试剂（胺、吡啶、叠氮化物、硫醇、羧酸、醇和18 O-水）反应，通过芳香族S N 1 机制产生苯酚的自身取代产物。尽管 Ph +在本体中的寿命稍纵即逝，但这项研究证明了其在水性微滴表面的异常稳定性，从而使其能够被检测和转化。

  DOI：

  10.1021/jacs.3c04662

文献信息

• COMPOUND AND DIMER COMPLEX EMBODIMENTS FOR SUPRAMOLECULAR SENSING
  申请人：UVic Industry Partnerships Inc.

  公开号：US20200407318A1

  公开（公告）日：2020-12-31

  Disclosed herein are embodiments of a compound that can be used as a supramolecular sensor for determining the presence of analytes (e.g., illicit drugs), and for identifying and/or quantifying the analytes. Also disclosed herein is a parallel synthesis method for making compound embodiments, as well as method embodiments for using the compound embodiments. Array embodiments comprising one or more compound embodiments disclosed herein also are described.

  本文披露了一种化合物的实施例，该化合物可用作超分子传感器，用于确定分析物（例如非法药物）的存在，并用于识别和/或定量分析物。还披露了一种用于制备化合物实施例的并行合成方法，以及用于使用化合物实施例的方法实施例。还描述了包括本文披露的一种或多种化合物实施例的阵列实施例。
• Malonamide Derivatives
  申请人：Bruge David

  公开号：US20070213374A1

  公开（公告）日：2007-09-13

  The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.

  本发明涉及公式A-D-B-1的马隆酰胺衍生物，作为raf-激酶的抑制剂，以及使用公式（I）化合物制备制药组合物的用途。
• Cycloalkyl-Hydroxyl Compounds and Compositions for Cholesterol Management and Related Uses
  申请人：Dasseux Henri Jean-Louis

  公开号：US20060229281A1

  公开（公告）日：2006-10-12

  The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型环烷基-羟基化合物、包含羟基化合物的组合物以及用于治疗和预防各种疾病和病况的方法，例如但不限于老化、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢紊乱、血脂异常、高血压、阳痿、炎症、胆汁中脂质排泄、肥胖症、胆汁中氧化固醇排泄、胰腺炎、帕金森病、过氧化物酶体增殖剂激活受体相关疾病、胆汁中磷脂排泄、肾脏疾病、败血症、X综合症、血栓性疾病。本发明的化合物和方法还可用于调节C反应蛋白或增强患者的胆汁产生。在某些实施例中，本发明的化合物、组合物和方法与其他治疗剂（例如降胆固醇和降血糖剂）一起使用可用于联合治疗。
• Benzimidazole carboxamides as raf kinase inhibitors
  申请人：Buchstaller Hans-Peter

  公开号：US20070093532A1

  公开（公告）日：2007-04-26

  The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase phathways, preferably by the raf kinase pathway, especially cancers.

  本发明涉及式（I）的苯并咪唑羧酰胺，以化合物式（I）作为一个或多个激酶的抑制剂，以化合物式（I）制备制药组合物的用途以及治疗方法，包括向患者给予该制药组合物。因此，式（I）的化合物或其药学上可接受的盐被用于治疗由一个或多个激酶途径介导的疾病，优选是通过raf激酶途径，特别是癌症。
• DIHYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
  申请人：Dasseux Jean-Louis Henri

  公开号：US20090247489A1

  公开（公告）日：2009-10-01

  The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型二羟基化合物、包含羟基化合物的组合物，以及用于治疗和预防各种疾病和病症的方法，例如但不限于老化、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢紊乱、血脂异常、高血压、阳痿、炎症、胰腺炎、帕金森病、过氧化物酶体增殖物激活受体相关疾病、胆汁中脂质消除、肥胖症、胆汁中氧化固醇消除、肾脏疾病、败血症、代谢综合症（例如综合征X）、血栓性疾病等。本发明的化合物和方法还可用于调节C反应蛋白或增强患者的胆汁产生。在某些实施例中，本发明的化合物、组合物和方法可与其他治疗剂（如降胆固醇和降血糖药物）结合使用。